Industry news

01 May 2017

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2017 Financial Results

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the "Company"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update and reported its financial results for the quarter ended March 31, 2017.

Further growth of Russian pharmaceutical market expected by its participants

GMP News

The participants in the Russian pharmaceutical market expect that, in the next two years, it will grow both in terms of monetary value and physical volumes, but consider the current state support measures for the industry as inadequate. Such conclusions can be drawn from a study conducted by IPT, a consulting group, and based on a survey of Russian and foreign pharmaceutical companies.

2017's first-quarter reports, with the newest from Big Pharma

FiercePharma

Every quarter, the FiercePharma team analyzes biopharma earnings reports and investor calls, and so far, the first quarter is a mixed bag. J&J saw key drugs shrink while Remicade held up under biosim attack; Lilly rolled out impressive sales growth amid pipeline questions; Novartis put up a couple of growth surprises in an otherwise unimpressive period—you get the picture.

27 April 2017

Syndax Announces Expansion of Immuno-Oncology Collaboration Evaluating Entinostat in Combination with KEYTRUDA(R) (pembrolizumab) for the Treatment of Colorectal Cancer

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), today announced the expansion of ENCORE 601/KEYNOTE 142, the ongoing Phase 2 clinical collaboration with a subsidiary of Merck, known as MSD outside the United States and Canada, to include a cohort of patients with microsatellite stable colorectal cancer.

The top 9 overseas accounts in biopharma hold $133B in M&A firepower

John Carroll / Endpoints News

During Amgen’s Q1 discussion with analysts on Wednesday evening, CEO Bob Bradway repeated one of the key themes in the land of Big Biopharma. Biotech valuations are high, he noted, making it difficult to acquire the kind of drug assets he’d like to lay his hands on.

Growth of Japanese Pharma Market Driven by Biologics and Generic Drugs, Says CPhI Report

BioPharm International

CPhI Japan, organized by UBM EMEA and UBM Asia, returned to Tokyo for its 16^th edition on April 19–21, 2017. New research into the Japanese pharmaceutical market was released at the show. More than 90 domestic and international companies who attended the event were surveyed to gauge growth opportunities in Japan. Domestic companies have projected a 17% growth in 2017, citing renewed buoyancy in the Japanese pharmaceutical economy following several years of limited growth.

The top 15 spenders in the global drug R&D business: 2017

John Carroll / Endpoints News

You usually don’t see much annual fluctuation in the overall R&D budgets of the top 15 companies. The trend over the last few years has been to keep the lid on spending, particularly among the giants in Big Pharma. Companies didn’t cut much overall, but there was plenty of realignment going on as the industry refocused pipelines and continued a migration to the big hubs.

Foreign investments in the Russian pharmaceutical industry exceeded 1 billion euros

GMP News

Dmitry Kurochkin, Vice-President of the Chamber of Commerce and Industry of the Russian Federation, said that, over the past few years, the Russian pharmaceutical industry showed a steady growth and is a leader compared to the other industries. The year-over-year growth consistently remains above 10%. For example, in 2016, the pharmaceutical industry grew by almost 24%. For 2016, the output of medicinal products reached 285.87 billion rubles. 77% of vital and essential drugs are already produced in Russia.

Partnering to fund clinical trials: A new model for pharma

Ben van der Schaaf / Europian Pharmaceutical Review

The US Department of Health and Human Services estimates suggest the cost of the clinical trial process today is upwards of $100 million, and that does not even take into account the marketing and distribution investment necessary for a pharmaceutical company to ensure new life enhancing therapies reach patients’ hands. The rising costs of drug development mean that despite building a robust pipeline of early stage compounds and indications, drug makers with robust R&D pipelines are losing billions each year in potential revenue as promising new therapies sit on the shelf waiting for their patent to expire.

EMA relocation's possible impact on safety monitoring 'alarming,' EU R&D chiefs say

Phil Talor / Fierce Biotech

As the saga of the EMA's location after Brexit rumbles on, European pharma leaders have drafted an open letter calling for strenuous efforts to avoid disruption at the regulator.